Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? - Wikidata - wikimedia - TriplyDB

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

http://www.wikidata.org/entity/Q35863874

about

Targeted therapy for advanced gastric cancer: A review of current status and future prospects Targeting receptor tyrosine kinases in gastric cancer The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.Pathogenetic mechanisms in gastric cancer.HER2/neu-directed therapy for biliary tract cancer.Effects of ophiopogonin B on the proliferation and apoptosis of SGC‑7901 human gastric cancer cells.Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer.Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).Gastric cancer-molecular and clinical dimensions.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Metastatic gastric cancer treatment: a little slow but worthy progress.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.A novel non-ATP competitive FGFR1 inhibitor with therapeutic potential on gastric cancer through inhibition of cell proliferation, survival and migration.Advances of Molecular Targeted Therapy in Gastric Cancer.High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.WAVE3 promotes epithelial-mesenchymal transition of gastric cancer through upregulation of Snail.Predictive biomarkers along gastric cancer pathogenetic pathways.High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma.Anti-metastatic activity of fangchinoline in human gastric cancer AGS cells.URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro.Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer.Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer.The function of Notch1 intracellular domain in the differentiation of gastric cancer.

P2860

Q26774138-2D1955CF-63CA-4524-8AE6-39D35CDC1795 Q27013050-876200F2-B053-4EFB-8976-C1B28B7DA385 Q27852562-C3B7B3C5-BB4F-45D2-8EC3-8979B9E77C25 Q30235387-74EBA94A-2EFB-49EC-A4BB-F0F35F3CE12A Q33557258-4224781E-A4CF-4302-9AEE-87A1B7CC29D4 Q33631305-9DBC1E58-5CAC-4591-A2F7-2EE25D15EDE1 Q34086875-6636B6B1-0015-43DF-A817-D3F10F538AF2 Q34309903-57349858-C581-439A-B7AA-7C0442396256 Q34326627-EEA343DF-CE67-41D4-ADDB-2238575B2ED2 Q35748129-1E625D2A-4A69-4D07-9A57-1CEB3DD5184B Q36001245-22DD1110-E8F2-4B02-BF31-5012FA0AF72F Q36952625-BCC12755-BCC7-48FD-83CE-87423BAAAE50 Q37247990-0A880B3A-EEF3-4D36-82F5-0E552E25FEFA Q37301452-ABDF24B9-FBB3-4641-8250-766015FB5FA6 Q37567784-98816BFF-3FEB-47C0-819C-05F324C2C2EE Q37591176-25C9C659-1320-418D-9B51-7D57881A255C Q38074157-4580114D-1417-4A20-B638-68BF65B28FF1 Q38075499-D1636262-7C50-460C-A747-D3BA178933A5 Q38210070-236BF61D-C887-43E8-963F-01C373EE48C3 Q38241766-9D36FF59-A64D-4C6C-90AE-6AE3875D9C6F Q38711736-BF2EC724-6858-470E-AECC-011BE1A0F705 Q38732700-38F39E83-8A52-45B0-88B2-691D1EE19E4E Q38882319-2E7C83F2-DE60-4383-ABB4-A42F23CC4DEC Q38942065-C0DB013A-F713-4E89-8623-B0D8140304F3 Q39170872-6744AB33-F97A-4488-A038-9D6CD05F9169 Q39470973-ED459892-0EFC-4C60-90C1-533FBB3DA4F7 Q42316338-B71CF02A-172E-4662-AA78-EFE9B09E259C Q42428140-91914D0A-0000-4FBC-8904-B773A7ABFAC3 Q45241774-B18FF54A-BDB8-4B82-8C5F-A88161831C18 Q49335261-2E3468F6-6CD5-4F27-AC3C-5EFD62CFB7FF Q52332705-E0DF1063-94DB-4D08-9214-CD8BAA8E7E4D

P2860

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

http://www.wikidata.org/entity/Q35863874

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Targeted therapy in the manage ...... era of personalized medicine?

@ast

Targeted therapy in the manage ...... era of personalized medicine?

@en

type

label

Targeted therapy in the manage ...... era of personalized medicine?

@ast

Targeted therapy in the manage ...... era of personalized medicine?

@en

prefLabel

Targeted therapy in the manage ...... era of personalized medicine?

@ast

Targeted therapy in the manage ...... era of personalized medicine?

@en

P1433

Q35863874-484178CE-7EE2-4A0C-8742-9CAE146BDE6D

P1476

Q35863874-F6ED0773-6115-4C81-B4CA-B53AB7431724

P2093

Q35863874-AC00964C-AF73-4CDC-AEE1-4E46F301B195

P2860

Q35863874-000A5C6E-B7F8-455B-94FB-A5E48876AC19

Q35863874-01AF94F6-0CF6-4EDC-B9D8-ADBAD89980AF

Q35863874-023FF732-0FB6-4C79-A1D6-0C8F3B2036AA

Q35863874-039CEACA-4A99-4C3D-A5B6-C56AB90A0FF2

Q35863874-0723551A-5D4A-4A7B-A29D-168B0E3B8720

Q35863874-07B51D50-99A3-4E9F-9028-8B88A4DE024B

Q35863874-089EBFBC-70A1-494E-A656-693C2B46F782

Q35863874-0A76CB16-6665-403B-AA72-72D31D14FB80

Q35863874-0BD4C9F2-448C-40A1-8240-0A5A9C14C66E

Q35863874-0C67E944-D32F-4360-9CB7-02D4241D4F46

P304

Q35863874-076D0277-C4C3-4715-88EF-A16EFC098AE2

P31

Q35863874-07380C34-CA0B-47A6-AF00-7D0A305B905C

P356

Q35863874-35BA394A-4217-4D26-AD90-A456248C663C

P433

Q35863874-2B26DFC2-07CA-46D4-897E-13C88A0B7310

P478

Q35863874-764F55DD-9508-4E52-A222-3EFD8D72F60C

P50

Q35863874-B1CAA0A3-CEA5-4A67-9DD0-24866643FC12

P577

Q35863874-4D7864EA-B42D-42EA-B780-46617631B937

P5875

Q35863874-25A8A066-2BC2-4C66-81D1-A014F4B9CC3E

P698

Q35863874-A0D9F40F-B9B4-488A-8C92-1ED927485E8D

P932

Q35863874-228FEED7-F685-414E-8D15-0653220CB18B

P356

THEONCOLOGIST.2011-0311

P1433

P1476

Targeted therapy in the manage ...... era of personalized medicine?

@en

P2093

Hilda Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of PIK3CA in gastric adenocarcinoma

Chemotherapy for advanced gastric cancer

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

The clonal evolution of tumor cell populations

Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers

P304

346-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2011-0311

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221832485

http://www.w3.org/2001/XMLSchema#string

P698

22334453

http://www.w3.org/2001/XMLSchema#string

P932

3316920

http://www.w3.org/2001/XMLSchema#string